BioSpace News Archive

Business

DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

DiaMedica Therapeutics Inc. today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14th .

March 8, 2022
·
1 min read
Biotech Bay

TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases

TRexBio Inc. today announced it has completed a $26 million extension of its Series A financing in a round led by new investor Polaris Partners.

March 8, 2022
·
3 min read
Biotech Beach

Fulgent Genetics Announces $250 Million Share Repurchase Program

Fulgent Genetics, Inc. announced that its Board of Directors has authorized a share repurchase program under which Fulgent may repurchase up to $250 million in shares of its common stock.

March 8, 2022
·
6 min read
Pharm Country

UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven

UroGen Pharma Ltd. announced the signing of an up to $100 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.

March 8, 2022
·
5 min read
Sanofi recognized by S&P as one of the most sustainability-committed companies

Sanofi was recognized as one of the most sustainability-committed companies in an ESG Evaluation performed by Standard & Poor’s Global Ratings.

March 8, 2022
·
6 min read
Business

Biocept Appoints Philippe Marchand as Chief Operating Officer

Biocept, Inc has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today.

March 8, 2022
·
4 min read
Business

Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results

Panbela Therapeutics, Inc. today announced that it will host a conference call on March 24, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021.

March 8, 2022
·
5 min read
Bio NC

TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation

A new TARGET-IBD study analysis shows one-third of patients with inflammatory bowel disease (IBD) did not have a record of objective disease activity assessment or therapeutic drug monitoring (TDM) prior to a biologic therapy dose change or discontinuation.

March 8, 2022
·
3 min read
BioCapital

CoapTech Announces IDE Approval from FDA to Initiate Clinical Trial for its PUMA-G Peds System for Pediatric Gastrostomy

CoapTech, Inc, announced today it has received an Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) to initiate a clinical trial for its PUMA-G Peds System, a device designed to provide a safer and more efficient way to place feeding tubes in children.

March 8, 2022
·
2 min read
Pharm Country

PAVmed to Hold a Business Update Conference Call on March 29, 2022

PAVmed Inc., a highly differentiated, multi-product, commercial-stage medical device company announced that the companies will host a business update conference call on Tuesday, March 29, 2022, at 4:30 PM EDT.

March 8, 2022
·
5 min read